Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer.
Larkina M, Plotnikov E, Bezverkhniaia E, Shabanova Y, Tretyakova M, Yuldasheva F, Zelchan R, Schulga A, Konovalova E, Vorobyeva A, Garousi J, Gräslund T, Belousov M, Tolmachev V, Deyev S. Larkina M, et al. Among authors: zelchan r. Int J Mol Sci. 2022 Nov 3;23(21):13443. doi: 10.3390/ijms232113443. Int J Mol Sci. 2022. PMID: 36362226 Free PMC article.
Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors.
Larkina M, Varvashenya R, Yuldasheva F, Plotnikov E, Bezverkhniaia E, Tretyakova M, Zelchan R, Schulga A, Konovalova E, Vorobyeva A, Belousov M, Orlova A, Tolmachev V, Deyev S. Larkina M, et al. Among authors: zelchan r. Mol Pharm. 2024 Apr 1;21(4):1919-1932. doi: 10.1021/acs.molpharmaceut.3c01173. Mol Pharm. 2024. PMID: 38557163
Phase I Clinical Evaluation of Designed Ankyrin Repeat Protein [99mTc]Tc(CO)3-(HE)3-Ec1 for Visualization of EpCAM-Expressing Lung Cancer.
Zelchan R, Chernov V, Medvedeva A, Rybina A, Bragina O, Mishina E, Larkina M, Varvashenya R, Fominykh A, Schulga A, Konovalova E, Vorobyeva A, Orlova A, Tashireva L, Deyev SM, Tolmachev V. Zelchan R, et al. Cancers (Basel). 2024 Aug 10;16(16):2815. doi: 10.3390/cancers16162815. Cancers (Basel). 2024. PMID: 39199590 Free PMC article.
Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu.
Machulkin AE, Petrov SA, Bodenko V, Larkina MS, Plotnikov E, Yuldasheva F, Tretyakova M, Bezverkhniaia E, Zyk NY, Stasyuk E, Zelchan R, Majouga AG, Tolmachev V, Orlova A, Beloglazkina EK, Yusubov MS. Machulkin AE, et al. Among authors: zelchan r. ACS Pharmacol Transl Sci. 2024 May 1;7(5):1457-1473. doi: 10.1021/acsptsci.4c00070. eCollection 2024 May 10. ACS Pharmacol Transl Sci. 2024. PMID: 38751647
Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors.
Chernov V, Rybina A, Zelchan R, Medvedeva A, Bragina O, Lushnikova N, Doroshenko A, Usynin E, Tashireva L, Vtorushin S, Abouzayed A, Rinne SS, Sörensen J, Tolmachev V, Orlova A. Chernov V, et al. Among authors: zelchan r. Cancers (Basel). 2023 Mar 7;15(6):1631. doi: 10.3390/cancers15061631. Cancers (Basel). 2023. PMID: 36980517 Free PMC article.
17 results